Preventing, stopping, or reversing coronary artery disease— triglyceride-rich lipoproteins and associated lipoprotein and metabolic abnormalities: The need for recognition and treatment

Ross, 1999, Atherosclerosis-an inflammatory disease, N Engl J Med, 340, 115, 10.1056/NEJM199901143400207 Grundy, 1990, Coronary heart disease in high-risk populations: lessons from Finland, Eur Heart J, 11, 462, 10.1093/oxfordjournals.eurheartj.a059730 Stamler, 1986, Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT), JAMA, 256, 2823, 10.1001/jama.1986.03380200061022 Superko, 1994, Coronary artery disease regression: convincing evidence for the benefit of aggressive lipoprotein management, Circulation, 90, 1056, 10.1161/01.CIR.90.2.1056 Ballantyne, 1997, Effects of lipid-lowering therapy on progression of coronary and carotid artery disease, Curr Opin Lipidol, 8, 354, 10.1097/00041433-199712000-00006 Superko, 1996, What can we learn about dense LDL and lipoprotein particles from clinical trials?, Curf Opin Lipidol, 7, 363, 10.1097/00041433-199612000-00004 Superko, 1996, Beyond LDL reduction, Circulation, 94, 2351, 10.1161/01.CIR.94.10.2351 1994, Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383 Shepherd, 1995, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, N Engl J Med, 333, 1301, 10.1056/NEJM199511163332001 Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, N Engl J Med, 335, 1001, 10.1056/NEJM199610033351401 Downs, 1998, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS, JAMA, 279, 1615, 10.1001/jama.279.20.1615 1998, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med, 339, 1349, 10.1056/NEJM199811053391902 1998, Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study, Circulation, 97, 1440, 10.1161/01.CIR.97.15.1440 Sacks, 1998, Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial, Circulation, 97, 1446, 10.1161/01.CIR.97.15.1446 Grundy, 1998, Statin trials and goals of cholesterol-lowering therapy, Circulation, 97, 1436, 10.1161/01.CIR.97.15.1436 Castelli, 1986, Incidence of coronary heart disease and lipoprotein-cholesterol levels: The Framingham Study, JAMA, 256, 2835, 10.1001/jama.1986.03380200073024 Superko, 1995, New aspects of cardiovascular risk factors including small, dense LDL, homocysteine, and Lp(a), Curr Opin Cardiol, 10, 347, 10.1097/00001573-199507000-00002 Pahor, 1999, Emerging noninvasive biochemical measures to predict cardiovascular risk, Arch Intern Med, 159, 237, 10.1001/archinte.159.3.237 Liao, 1998, Endothelium and the acute coronary syndromes, Clin Chem, 44, 1799, 10.1093/clinchem/44.8.1799 Lagrand, 1999, C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?, Circulation, 100, 96, 10.1161/01.CIR.100.1.96 Libby, 1997, Roles of infectious agents in atherosclerosis and restenosis, Circulation, 96, 4095, 10.1161/01.CIR.96.11.4095 Kannel, 1995, Range of serum cholesterol values in the population developing coronary artery disease, Am J Cardiol, 76, 69C, 10.1016/S0002-9149(99)80474-3 Grundy, 1997, atherogenic dyslipidemia, and the metabolic syndrome, Circulation, 95, 1, 10.1161/01.CIR.95.1.1 Otvos, 1999, Measurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy, Clin Cardiol, 22, II Albrink, 1959, Serum triglycerides in coronary artery disease, Arch Intern Med, 103, 4, 10.1001/archinte.1959.00270010010002 Goldstein, 1973, Hyperlipidemia in coronary heart disease, I: lipid levels in 500 survivors of myocardial infarction, J Clin Invest, 52, 1533, 10.1172/JCI107331 Castelli, 1977, HDL cholesterol and other lipids in coronary heart disease: The Cooperative Lipoprotein Phenotyping Study, Circulation, 55, 767, 10.1161/01.CIR.55.5.767 Carlson, 1979, Risk factors for myocardial infarction in the Stockholm Prospective Study: a l4-year follow-up focusing on the role of plasma triglyceride and cholesterol, Acta Med Scand, 206, 351, 10.1111/j.0954-6820.1979.tb13526.x Gotto, 1977, Relationship between plasma lipid concentration and coronary artery disease in 496 patients, Circulation, 56, 875, 10.1161/01.CIR.56.5.875 Sprecher, 1998, Triglycerides as a risk factor for coronary artery disease, Am J Cardiol, 82, 49U, 10.1016/S0002-9149(98)00953-9 Gotto, 1998, Triglycerides as a risk factor for coronary artery disease, Am J Cardiol, 82, 22Q, 10.1016/S0002-9149(98)00770-X Packard, 1999, Physiology of the lipoprotein transport system: an overview of lipoprotein metabolism, 17 Ginsberg, 1999, VLDL/LDL cascade system: assembly, secretion, and intravascular metabolism of apoprotein B-containing lipoproteins, 55 Yamashita, 1999, Cholesteryl ester transfer protein, 277 Eisenberg, 1999, High-density lipoprotein metabolism, 71 Brunzell, 1989, Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome, 1165 Gerdes, 1995, Polymorphisms in the lipoprotein lipase and their associations with plasma lipid concentration in 40-year-old Danish men, Circulation, 92, 1765, 10.1161/01.CIR.92.7.1765 Tall, 1986, Plasma lipid transfer proteins, J Lipid Res, 27, 361, 10.1016/S0022-2275(20)38819-2 Krauss, 1994, Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk, Cuff Opin Lipidol, 5, 339, 10.1097/00041433-199410000-00005 Krauss, 1998, Atherogenicity of triglyceride-rich lipoproteins, Am J Cardiol, 81, 13B, 10.1016/S0002-9149(98)00032-0 Hodis, 1999, Pathophysiology of triglyceriderich lipoproteins in atherothrombosis: clinical aspects, Clin Cardiol, 22, II Hodis, 1999, Triglyceride-rich lipoprotein remnants and risk of atherosclerosis, Circulation, 99, 2852, 10.1161/01.CIR.99.22.2852 Alaupovic, 1991, Apolipoprotein composition as the basis for classifying plasma lipoproteins, Prog Lipid Res, 30, 105, 10.1016/0163-7827(91)90008-S Grundy, 1992, Two different views of the relationship of hypertriglyceridemia to coronary heart disease: implications for treatment, Arch Intern Med, 152, 28, 10.1001/archinte.1992.00400130054004 Gianturco, 1999, Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: cellular aspects, Clin Cardiol, 22, II Benlian, 1996, Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene, N Engl J Med, 335, 848, 10.1056/NEJM199609193351203 Anderson, 1999, Association of lipoprotein lipase gene polymorphisms with coronary artery disease, J Am Coll Cardiol, 33, 1013, 10.1016/S0735-1097(98)00677-9 Wittrup, 1999, Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic disease: a meta-analysis, Circulation, 99, 2901, 10.1161/01.CIR.99.22.2901 Gofman, 1966, Ischemic heart disease, atherosclerosis, and longevity, Circulation, 34, 679, 10.1161/01.CIR.34.4.679 Gofman, 1954, The serum lipoprotein transport system in health, metabolic disorders, atherosclerosis, and coronary disease, Plasma, 2, 413 Lindgren, 1951, The ultracentrifugal characterization and isolation of human blood lipids and lipoproteins with applications to the study of atherosclerosis, J Phys Colloid Chem, 55, 80, 10.1021/j150484a010 Chung, 1991, Cytotoxicity of remnants of triglyceride-rich lipoproteins: an atherogenic insult, Adv Exp Med Biol, 285, 341, 10.1007/978-1-4684-5904-3_42 Schaefer, 1986, Familial apolipoprotein E deficiency, J Clin Invest, 78, 1206, 10.1172/JCI112704 Mahley, 1995, Type III hyperlipidemia (dysbetalipoproteinemia): The role of apolipoprotein E in normal and abnormal lipoprotein metabolism, 1953 Frost, 1998, Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy, Am J Cardiol, 81, 26B, 10.1016/S0002-9149(98)00034-4 Krauss, 1987, Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolemic men, Lancet, 2, 62, 10.1016/S0140-6736(87)92734-6 Krauss, 1987, Relationship of intermediate and low-density lipoprotein subspecies to risk of coronary artery disease, Am Heart J, 113, 578, 10.1016/0002-8703(87)90636-3 Grundy, 1998, Consensus statement: role of therapy with “statins” in patients with hypertriglyceridemia, Am J Cardiol, 81, 1B, 10.1016/S0002-9149(98)00030-7 Grundy, 1998, Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome, Am J Cardiol, 81, 18B, 10.1016/S0002-9149(98)00033-2 Austin, 1990, Atherogenic lipoprotein phenotype: A proposed genetic marker for coronary heart disease risk, Circulation, 82, 495, 10.1161/01.CIR.82.2.495 Austin, 1994, Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance, Curr Opin Lipidol, 5, 395, 10.1097/00041433-199412000-00002 Superko, 1998, Small dense LDL: the new coronary artery disease risk factor and how it is changing the treatment of CAD, Prev Cardiol, 1, 16 Reaven, 1993, Insulin resistance and hyperinsulinemia in individuals with small, dense, low-density lipoprotein particles, J Clin Invest, 92, 141, 10.1172/JCI116541 Austin, 1995, Prospective study of small LDLs as a risk factor for non-insulin-dependent diabetes mellitus in elderly men and women, Circulation, 92, 1770, 10.1161/01.CIR.92.7.1770 1994, Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II), Circulation, 89, 1329 Gordon, 1990, Role of circulating high-density lipoprotein and triglycerides in coronary artery disease: risk and prevention, Endocrinol Metabol Clin North Am, 19, 299, 10.1016/S0889-8529(18)30326-8 Miller, 1992, Long-term predictors of subsequent cardiovascular events with coronary artery disease and “desirable” levels of plasma total cholesterol, Circulation, 86, 1165, 10.1161/01.CIR.86.4.1165 Burchfiel, 1995, Combined effects of HDL cholesterol, triglyceride, and total cholesterol concentrations on 18-year risk of atherosclerotic disease, Circulation, 92, 1430, 10.1161/01.CIR.92.6.1430 Corti, 1995, HDL cholesterol predicts coronary heart disease mortality in older persons, JAMA, 274, 539, 10.1001/jama.1995.03530070037026 Paunio, 1994, HDL cholesterol and mortality in Finnish men with special reference to alcohol intake, Circulation, 90, 2909, 10.1161/01.CIR.90.6.2909 Atger, 1995, Highdensity lipoprotein subfractions as markers of early atherosclerosis, Am J Cardiol, 75, 127, 10.1016/S0002-9149(00)80060-0 Lien, 1996, Low-serum, highdensity lipoprotein cholesterol concentration is an important coronary risk factor in Chinese patients with low serum levels of total cholesterol and triglyceride, Am J Cardiol, 77, 1112, 10.1016/S0002-9149(96)00144-0 Frost, 1996, Coronary heart disease risk factors in men and women aged 60 years and older, Circulation, 94, 26, 10.1161/01.CIR.94.1.26 Austin, 1991, Plasma triglyceride and coronary heart disease, Arterioscler Thromb, 11, 2, 10.1161/01.ATV.11.1.2 Criqui, 1993, Plasma triglyceride level and mortality from coronary heart disease, N Engl J Med, 328, 1220, 10.1056/NEJM199304293281702 Criqui, 1998, Epidemiologic aspects of lipid abnormalities, Am J Med, 105, 48S, 10.1016/S0002-9343(98)00212-5 Gardner, 1996, Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women, JAMA, 276, 875, 10.1001/jama.1996.03540110029028 Miller, 1975, Plasma high-density lipoprotein concentration and development of ischemic heart disease, Lancet, 1, 16, 10.1016/S0140-6736(75)92376-4 Gordon, 1977, High-density lipoprotein as a protective factor against coronary heart disease: the Framingham Study, Am J Med, 62, 707, 10.1016/0002-9343(77)90874-9 Hokanson, 1996, Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a metaanalysis of population-based prospective studies, J Cardiovasc Risk, 3, 213, 10.1097/00043798-199604000-00014 Byberg, 1998, Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men, Arterioscler Thromb Vasc Biol, 18, 258, 10.1161/01.ATV.18.2.258 Miller, 1986, Association between dietary fat intake and plasma factor VII coagulant activity—a predictor of cardiovascular mortality, Atherosclerosis, 60, 269, 10.1016/0021-9150(86)90174-7 Miller, 1985, Assay of factor VII activity by two techniques: evidence for increased conversion of VII to alpha VIIa in hyperlipidemia with possible implications for ischemic heart disease, Br J Haematol, 59, 249, 10.1111/j.1365-2141.1985.tb02991.x Miller, 1991, Plasma factor VII is activated by postprandial triglyceridemia, irrespective of dietary fat composition, Atherosclerosis, 86, 163, 10.1016/0021-9150(91)90212-L Green, 1994, Hemostatic factors in the Coronary Artery Risk Development in Young Adults (CARDIA) Study, Arterioscler Thromb, 14, 686, 10.1161/01.ATV.14.5.686 Mussoni, 1992, Hypertriglyceridemia and regulation of fibrinolytic activity, Arterioscler Thromb, 12, 19, 10.1161/01.ATV.12.1.19 Simpson, 1983, Hypertriglyceridemia and hypercoagulability, Lancet, I, 786, 10.1016/S0140-6736(83)91849-4 Vogel, 1997, Effect of a single high-fat meal on endothelial function in healthy subjects, Am J Cardiol, 79, 350, 10.1016/S0002-9149(96)00760-6 Patsch, 1992, Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state, Arterioscler Thromb, 12, 1336, 10.1161/01.ATV.12.11.1336 Sharrett, 1995, Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women: the Atherosclerosis Risk in Communities (ARIC) Study, Arterioscler Thromb Vase Biol, 15, 2122, 10.1161/01.ATV.15.12.2122 Karpe, 1994, Postprandial lipoproteins and progression of coronary atherosclerosis, Atherosclerosis, 106, 83, 10.1016/0021-9150(94)90085-X Uiterwaal, 1994, Postprandial triglyceride response in young adult men and familial risk for coronary atherosclerosis, Ann Intern Med, 121, 576, 10.7326/0003-4819-121-8-199410150-00004 Karpe, 1999, Differences in postprandial concentrations of very-low density lipoprotein and chylomicron remnants between normotriglyceridemic and hypertriglyceridemic men with and without coronary heart disease, Metabolism, 48, 301, 10.1016/S0026-0495(99)90076-8 Marx, 1995, Does gemfibrozil prevent coronary disease by reduction of postprandial triglyceride-rich lipoproteins? Differences between triglyceride/HDL subgroups, Circulation, 92, I O'Keefe, 1995, Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia, Am J Cardiol, 76, 480, 10.1016/S0002-9149(99)80134-9 Nikkila, 1994, Postprandial plasma lipoprotein changes in relation to apolipoprotein E phenotypes and low-density lipoprotein size in men with and without coronary heart disease, Atherosclerosis, 106, 149, 10.1016/0021-9150(94)90120-1 Ginsberg, 1995, Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women, Arterioscler Thromb Vase Biol, 15, 1829, 10.1161/01.ATV.15.11.1829 Schaefer, 1994, Familial lipoprotein disorders and premature coronary artery disease, Med Clin North Am, 78, 21, 10.1016/S0025-7125(16)30175-4 Janus, 1980, Kinetic bases of the primary hyperlipidemias: studies of apolipoprotein B turnover in genetically defined subjects, Eur J Clin Invest, 10, 161, 10.1111/j.1365-2362.1980.tb02076.x Kissebah, 1981, Integrated regulation of very low-density lipoprotein, triglycerides, and apolipoprotein-B kinetics in man: normolipemic subjects, familial hypertriglyceridemia, and familial combined hyperlipidemia, Metabolism, 30, 856, 10.1016/0026-0495(81)90064-0 Genest, 1992, Familial lipoprotein disorders in patients with premature coronary artery disease, Circulation, 85, 2025, 10.1161/01.CIR.85.6.2025 Goldstein, 1973, Hyperlipidemia in coronary heart disease: II—genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia, J Clin Invest, 52, 1544, 10.1172/JCI107332 Stone, 1998, Management of lipids in clinical practice, 60 Castelli, 1988, Cholesterol and lipids in the risk of coronary artery disease: the Framingham Heart Study, Can J Cardiol, 4, 5A Hulley, 1980, Epidemiology as a guide to clinical decisions: the association between triglyceride and coronary heart disease, N Engl J Med, 302, 1383, 10.1056/NEJM198006193022503 Assmann, 1992, Role of triglycerides in coronary disease: lessons from the Prospective Cardiovascular Muenster Study, Am J Cardiol, 70, 10H, 10.1016/0002-9149(92)91084-H Assmann, 1992, Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (The PROCAM experience), Am J Cardiol, 70, 733, 10.1016/0002-9149(92)90550-I Castelli, 1992, Epidemiology of triglycerides: a view from Framingham, Am J Cardiol, 70, 3H, 10.1016/0002-9149(92)91083-G Bainton, 1992, Plasma triglyceride and high-density lipoprotein cholesterol as predictors of ischemic heart disease in British men: the Caerphilly and Speedwell Collaborative Heart Disease Studies, Br Heart J, 68, 60, 10.1136/hrt.68.7.60 Assmann, 1996, Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men, Am J Cardiol, 77, 1179, 10.1016/S0002-9149(96)00159-2 Jeppesen, 1998, Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study, Circulation, 97, 1029, 10.1161/01.CIR.97.11.1029 Cambien, 1986, Is the level of serum triglyceride a significant predictor of coronary death in “normocholesterolemic” subjects?, Am J Epidemiol, 124, 624, 10.1093/oxfordjournals.aje.a114435 Miller, 1998, Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study, J Am Coll Cardiol, 31, 1252, 10.1016/S0735-1097(98)00083-7 Austin, 1998, Hypertriglyceridemia as a cardiovascular risk factor, Am J Cardiol, 81, 7B, 10.1016/S0002-9149(98)00031-9 1993, Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II), JAMA, 269, 3015, 10.1001/jama.1993.03500230097036 Miller, 1999, The epidemiology of triglycerides as a coronary artery disease risk factor, Clin Cardiol, 22, II-1, 10.1002/clc.4960221402 Tailleux, 1996, HDL heterogeneity and atherosclerosis, Crit Rev Clin Lab Sci, 33, 163, 10.3109/10408369609083060 Fielding, 1995, Molecular physiology of reverse cholesterol transport, J Lipid Res, 36, 211, 10.1016/S0022-2275(20)39898-9 O'Connor, 1998, Pre-beta-1 HDL in plasma of normolipidemic individuals: Influences of plasma lipoproteins, age and gender, J Lipid Res, 39, 670, 10.1016/S0022-2275(20)33304-6 Tall, 1998, An overview of reverse cholesterol transport, Eur Heart J, 19, A31 Acton, 1996, Identification of scavenger receptor SR-BI as a high-density lipoprotein receptor, Science, 271, 518, 10.1126/science.271.5248.518 Krieger, 1998, The “best” of cholesterols, the “worst” of cholesterols: a tale of two receptors, 95, 4077 Kwiterovich, 1998, The anti-atherogenic role of high-density lipoprotein cholesterol, Am J Cardiol, 82, 13Q, 10.1016/S0002-9149(98)00808-X Dansky, 1999, High-density lipoprotein and plaque regression: the good cholesterol gets even better, Circulation, 100, 1762, 10.1161/01.CIR.100.17.1762 Tangirala, 1999, Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice, Circulation, 100, 1816, 10.1161/01.CIR.100.17.1816 Parthasarathy, 1990, High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein, Biochem Biophys Acta, 1044, 275, 10.1016/0005-2760(90)90314-N Saku, 1985, Activation of fibrinolysis by apolipoproteins of high-density lipoproteins in man, Thromb Res, 39, 1, 10.1016/0049-3848(85)90116-1 Barter, 1996, High-density lipoproteins and coronary heart disease, Atherosclerosis, 121, 1, 10.1016/0021-9150(95)05675-0 Havel, 1973, Interchange of apolipoproteins between chylomicrons and high-density lipoproteins during alimentary lipemia in man, J Clin Invest, 52, 32, 10.1172/JCI107171 Gordon, 1989, High-density lipoprotein cholesterol and cardiovascular disease: four prospective American series, Circulation, 79, 8, 10.1161/01.CIR.79.1.8 Castelli, 1992, Lipids and risk of coronary heart disease: The Framingham Study, Ann Epidemiol, 2, 23, 10.1016/1047-2797(92)90033-M Genest, 1992, Lipoprotein cholesterol, apolipoprotein A-1 and B, and Lipoprotein (a) abnormalities in men with premature coronary artery disease, J Am Coll Cardiol, 19, 792, 10.1016/0735-1097(92)90520-W Castelli, 1977, HDL cholesterol and other lipids in coronary heart disease: the Cooperative Lipoprotein Phenotyping Study, Circulation, 55, 767, 10.1161/01.CIR.55.5.767 Pearson, 1979, The association of low levels of HDL cholesterol and arteriographically defined coronary artery disease, Am J Epidemiol, 109, 285, 10.1093/oxfordjournals.aje.a112682 Shah, 1992, Low, high-density lipoprotein level is associated with increased re-stenosis rate after coronary angioplasty, Circulation, 85, 1279, 10.1161/01.CIR.85.4.1279 Dzavik, 1995, Effect of serum lipid concentration on re-stenosis after successful de novo percutaneous transluminal coronary angioplasty in patients with total cholesterol 160–240 mg/dL and triglycerides <350 mg/dL, Am J Cardiol, 75, 936, 10.1016/S0002-9149(99)80691-2 Burke, 1997, Coronary risk factors and plaque morphology in men with coronary disease who died suddenly, N Engl J Med, 336, 1276, 10.1056/NEJM199705013361802 Rubins, 1999, Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol, N Engl J Med, 341, 410, 10.1056/NEJM199908053410604 Laakso, 1985, Association of low HDL and HDL2 cholesterol with coronary heart disease in non-insulin-dependent diabetics, Arteriosclerosis, 5, 653, 10.1161/01.ATV.5.6.653 Hamsten, 1986, Relationship of angiographically defined coronary heart disease to serum lipoproteins and apolipoproteins in young survivors of myocardial infarction, Circulation, 73, 1097, 10.1161/01.CIR.73.6.1097 Franceschini, 1987, Reduced HDL2 levels in myocardial infarction patients without risk factors for atherosclerosis, Atherosclerosis, 68, 213, 10.1016/0021-9150(87)90200-0 Ballantyne, 1982, High density and low density lipoprotein subfractions in survivors of myocardial infarction and in control subjects, Metabolism, 31, 433, 10.1016/0026-0495(82)90230-X Stampfer, 1991, A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction, N Engl J Med, 325, 373, 10.1056/NEJM199108083250601 Salonen, 1991, HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction: a prospective population study in Eastern Finnish men, Circulation, 84, 129, 10.1161/01.CIR.84.1.129 Nichols, 1986, Nondenaturing polyacrylamide gradient gel electrophoresis, Methods Enzymol, 128, 417, 10.1016/0076-6879(86)28084-2 Wilson, 1993, Alterations in the concentration of an apolipoprotein E-containing subfraction of plasma high-density lipoprotein in coronary heart disease, Clin Chim Acta, 220, 175, 10.1016/0009-8981(93)90046-7 Johansson, 1991, High-density lipoproteins and coronary atherosclerosis: a strong inverse relation with the largest particles is confined to normotriglyceridemic patients, Arterioscler Thromb, 11, 174, 10.1161/01.ATV.11.1.174 Wilson, 1990, The distribution of high-density lipoprotein subfractions in coronary survivors, Biochem Soc Trans, 18, 1175, 10.1042/bst0181175 Cheung, 1991, Altered particle size distribution of apolipoprotein A-1-containing lipoproteins in subjects with coronary artery disease, J Lipid Res, 32, 383, 10.1016/S0022-2275(20)42061-9 Fievet, 1991, HDL heterogeneity and coronary heart disease, Diabetes Metab Rev, 7, 155, 10.1002/dmr.5610070304 Miller, 1987, Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis, Am Heart J, 113, 589, 10.1016/0002-8703(87)90638-7 Williams, 1992, Associations of lipoproteins and apolipoproteins with gradient gel electrophoresis estimates of high density lipoprotein subfractions in men and women, Arterioscler Thromb Vasc Biol, 12, 232, 10.1161/01.ATV.12.3.332 Otvos, 1992, Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement, Clin Chem, 38, 1622, 10.1093/clinchem/38.9.1632 Freedman, 1998, Relation of lipoprotein subclasses as measured by proton nuclear magnetic spectroscopy to coronary artery disease, Arterioscler Thromb Vasc Biol, 18, 1046, 10.1161/01.ATV.18.7.1046 Stampfer, 1996, A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction, JAMA, 276, 882, 10.1001/jama.1996.03540110036029 Sweetnam, 1994, Associations of the HDL2 and HDL3 cholesterol subfractions with the development of ischemic heart disease in British men: the Caerphilly and Speedwell Collaborative Heart Disease Studies, Circulation, 90, 769, 10.1161/01.CIR.90.2.769 Lamarche, 1997, Associations of HDL2 and HDL3 with ischemic heart disease in men: prospective results for the Quebec Cardiovascular Study, Arterioscler Thromb Vasc Biol, 17, 1098, 10.1161/01.ATV.17.6.1098 Lagrost, 1994, Combined effects of lipid transfers and lipolysis on gradient gel patterns of human plasma LDL, Arterioscler Thromb, 14, 1327, 10.1161/01.ATV.14.8.1327 McNamara, 1992, Change in LDL particle size is associated with change in plasma triglyceride concentration, Arterioscler Thromb, 12, 1284, 10.1161/01.ATV.12.11.1284 Coresh, 1993, Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women, J Lipid Res, 34, 1687, 10.1016/S0022-2275(20)35731-X Austin, 1995, Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women, Circulation, 92, 1770, 10.1161/01.CIR.92.7.1770 Musliner, 1986, Presence of multiple subpopulations of lipoproteins of intermediate density in normal subjects, Arteriosclerosis, 6, 79, 10.1161/01.ATV.6.1.79 Zambon, 1993, Effect of hepatic lipase on LDL in normal men and those with coronary artery disease, Arterioscler Thromb, 13, 147, 10.1161/01.ATV.13.2.147 Austin, 1986, Genetic control of low-density lipoprotein subclasses, Lancet, 2, 592, 10.1016/S0140-6736(86)92425-6 Austin, 1992, Genetic epidemiology of low-density lipoprotein subclass phenotypes, Ann Med, 24, 477, 10.3109/07853899209166999 Campos, 1992, LDL particle size distribution: results from the Framingham Offspring Study, Arterioscler Thromb, 12, 1410, 10.1161/01.ATV.12.12.1410 Selby, 1993, LDL subclass phenotypes and the insulin resistance syndrome in women, Circulation, 88, 381, 10.1161/01.CIR.88.2.381 Tall, 1990, Plasma high-density lipoproteins. Metabolism and relationship to atherogenesis, J Clin Invest, 86, 379, 10.1172/JCI114722 Dixon, 1991, Oleic acid stimulates secretion of ApoB-containing lipoproteins from HepG2 cells by reducing intracellular degradation of ApoB, J Biol Chem, 266, 5080, 10.1016/S0021-9258(19)67758-6 Randle, 1963, The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus, Lancet, 1, 785, 10.1016/S0140-6736(63)91500-9 Campos, 1991, Variations in hepatic lipase and lipoprotein lipase activities associated with low-density lipoprotein subclass patterns, Circulation, 84, 11 Campos, 1992, Low-density lipoprotein particle size and coronary artery disease, Arterioscler Thromb, 12, 187, 10.1161/01.ATV.12.2.187 Austin, 1988, Low-density lipoprotein subclass patterns and risk of myocardial infarction, JAMA, 260, 1917, 10.1001/jama.1988.03410130125037 Crouse, 1985, Studies of low-density lipoprotein molecular weight in human beings with coronary artery disease, J Lipid Res, 26, 566, 10.1016/S0022-2275(20)34343-1 Tornvall, 1991, Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction, Atherosclerosis, 90, 67, 10.1016/0021-9150(91)90245-X Stampfer, 1996, A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction, JAMA, 276, 882, 10.1001/jama.1996.03540110036029 Gardner, 1996, Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women, JAMA, 276, 875, 10.1001/jama.1996.03540110029028 Lamarche, 1997, Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study, Circulation, 95, 69, 10.1161/01.CIR.95.1.69 DeGraaf, 1991, Enhanced susceptibility to in vitro oxidation of the dense low-density lipoprotein subfraction in healthy subjects, Arterioscler Thromb, 11, 298, 10.1161/01.ATV.11.2.298 Tribble, 1992, Variations in oxidative susceptibility among six low-density lipoprotein subfractions of differing density and particle size, Atherosclerosis, 93, 189, 10.1016/0021-9150(92)90255-F Chait, 1993, Susceptibility of small, dense, lowdensity lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B, Am J Med, 94, 350, 10.1016/0002-9343(93)90144-E Dejager, 1993, Dense, low-density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia, J Lipid Res, 34, 295, 10.1016/S0022-2275(20)40756-4 Dyce, 1993, Indices of LDL particle size closely relate to endothelial function, Circulation, 88, I-466 Anderson, 1996, Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans, Circulation, 93, 1647, 10.1161/01.CIR.93.9.1647 Selwyn, 1997, Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease, Circulation, 95, 5, 10.1161/01.CIR.95.1.5 Nielsen, 1996, Transfer of low-density lipoprotein into the arterial wall and risk of atherosclerosis, Atherosclerosis, 123, 1, 10.1016/0021-9150(96)05802-9 Bjomheden, 1996, Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system, Atherosclerosis, 123, 43, 10.1016/0021-9150(95)05770-6 Coresh, 1996, Small, dense, low-density lipoprotein particles and coronary heart risk: a clear association with uncertain implications, JAMA, 276, 914, 10.1001/jama.1996.03540110068034 Austin, 1999, Low-density lipoprotein particle size is a risk factor for coronary heart disease independent of triglyceride and HDL cholesterol: a meta-analysis of three prospective studies in men, Circulation, 99, I-1124 Austin, 1992, Bimodality of plasma apolipoprotein B levels in familial combined hyperlipidemia, Atherosclerosis, 92, 67, 10.1016/0021-9150(92)90011-5 Teng, 1983, Composition and distribution of low-density lipoprotein fractions in hyperapobetalipoproteinemia normolipidemia, and familial hypercholesterolemia, 80, 6662 Genest, 1993, Familial hypoalphalipoproteinemia in premature coronary artery disease, Arterioscler Thromb, 13, 1728, 10.1161/01.ATV.13.12.1728 Brown, 1996, Impact of management in stabilization of coronary disease, 191 Fuster, 1992, The pathogenesis of coronary artery disease and the acute coronary syndromes, N Engl J Med, 326, 242, 10.1056/NEJM199201233260406 Fuster, 1992, The pathogenesis of coronary artery disease and the acute coronary syndromes, N Engl J Med, 326, 310, 10.1056/NEJM199201303260506 Brown, 1993, Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease, Circulation, 87, 1781, 10.1161/01.CIR.87.6.1781 Brensike, 1984, Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study, Circulation, 69, 313, 10.1161/01.CIR.69.2.313 Miller, 1993, Baseline triglyceride levels predict angiographic benefit of colestipol plus niacin therapy in the Cholesterol-Lowering Atherosclerosis Study (CLAS), Circulation, 88, I Hodis, 1995, Triglyceride-rich lipoproteins and the progression of coronary artery disease, Curf Opin Lipidol, 6, 209, 10.1097/00041433-199508000-00004 Blankenhorn, 1990, Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and non-lipid factors, Circulation, 81, 470, 10.1161/01.CIR.81.2.470 Blankenhorn, 1987, Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts, JAMA, 257, 3233, 10.1001/jama.1987.03390230069027 Cashin-Hemphill, 1990, Beneficial effects of colestipol-niacin on coronary atherosclerosis: a four-year followup, JAMA, 264, 3013, 10.1001/jama.1990.03450230049028 Koren, 1996, Triglyceride-enriched lipoprotein particles correlate with the severity of coronary artery disease, Atherosclerosis, 122, 105, 10.1016/0021-9150(95)05791-9 Phillips, 1993, Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events, Circulation, 88, 2762, 10.1161/01.CIR.88.6.2762 Mack, 1996, Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS): treatment effects and relation to coronary angiographic progression, Arterioscler Thromb Vase Biol, 16, 697, 10.1161/01.ATV.16.5.697 Hodis, 1994, Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin, Circulation, 90, 42, 10.1161/01.CIR.90.1.42 Blankenhorn, 1993, Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS), Ann Intern Med, 119, 969, 10.7326/0003-4819-119-10-199311150-00002 Alaupovic, 1997, The role of triglyceride-rich lipoprotein families in the progression of atherosclerosic lesions as determined by sequential coronary angiography from a controlled clinical trial, Arterioscler Thromb Vasc Biol, 17, 715, 10.1161/01.ATV.17.4.715 Miller, 1994, Predominance of mid-density/low-density lipoproteins predicts angiographic benefit of lovastatin in the Monitored Atherosclerosis Regression Study, Circulation, 90, I Hodis, 1997, Intermediate-density lipoproteins and progression of carotid arterial wall intimamedia thickness, Circulation, 95, 2022, 10.1161/01.CIR.95.8.2022 Watts, 1992, Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS), Lancet, 339, 563, 10.1016/0140-6736(92)90863-X Watts, 1993, Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS), Metabolism, 42, 1461, 10.1016/0026-0495(93)90199-X Miller, 1996, Predominance of dense, low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project, Circulation, 94, 2146, 10.1161/01.CIR.94.9.2146 Haskell, 1994, The effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical events in men and women with coronary artery disease: the Stanford Coronary Risk Intervention Project (SCRIP), Circulation, 89, 975, 10.1161/01.CIR.89.3.975 Zambon, 1996, Hepatic lipase changes predicts coronary artery disease regression/progression in the Familial Atherosclerosis Treatment Study, Circulation, 94, I Stewart, 1994, Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low-density lipoprotein cholesterol, J Am Coll Cardiol, 23, 899, 10.1016/0735-1097(94)90635-1 Brown, 1998, Very intensive lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction: a 10-year Familial Atherosclerosis Treatment Study (FATS) follow-up, Circulation, 98, I West, 1996, The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia, Control Clin Trials, 17, 550, 10.1016/S0197-2456(96)00178-X Herd, 1997, Effects of fluvastatin on coronary atherosclerosis in patients with mild-tomoderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study-LCAS), Am J Cardiol, 80, 278, 10.1016/S0002-9149(97)00346-9 Ballantyne, 1999, Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy, Circulation, 99, 736, 10.1161/01.CIR.99.6.736 Frick, 1997, Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol: Lopid Coronary Angiography Trial (LOCAT) Study Group, Circulation, 96, 2137, 10.1161/01.CIR.96.7.2137 Ericsson, 1996, Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients, Lancet, 347, 849, 10.1016/S0140-6736(96)91343-4 Ruotolo, 1998, J Am Card Cardiol, 32, 1648, 10.1016/S0735-1097(98)00442-2 Austin, 1987, Low-density lipoprotein subclass patterns and risk of myocardial infarction: the Boston Area Health Study, Am J Epidemiol, 126, 739 Carlson, 1988, Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid, Acta Med Scanda, 223, 405, 10.1111/j.0954-6820.1988.tb15891.x Frick, 1987, Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease, N Engl J Med, 317, 1237, 10.1056/NEJM198711123172001 Manninen, 1988, Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study, JAMA, 260, 641, 10.1001/jama.1988.03410050061031 Manninen, 1992, Joint effects of serum triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment, Circulation, 85, 37, 10.1161/01.CIR.85.1.37 Sacks, 1998, New lipoprotein predictors of recurrent coronary events: VLDL particle concentration, VLDL lipid content, and apolipoproteins C-III and E, Circulation, 98, I 1995, Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S), Lancet, 345, 1274, 10.1016/S0140-6736(95)90926-5 Kesaniemi, 1998, Serum triglycerides and clinical benefit in lipid-lowering trials, Am J Cardiol, 814A, 70B, 10.1016/S0002-9149(98)00042-3 Pedersen, 1998, Lipoprotein changes and reduction in the incidence of major coronary heart disease events in, Circulation, 97, 1453, 10.1161/01.CIR.97.15.1453 Ferguson, 1999, Bezafibrate Infarction Prevention Trial, 99, 1131 Goldbourt, 1993, Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (The Bezafibrate Infarction Prevention Trial), Am J Cardiol, 71, 909, 10.1016/0002-9149(93)90905-R 1998, 40, 117 Stone, 1999, 2, 1 Vega, 1990, Management of primary mixed hyperlipidemia with lovastatin, Arch Intern Med, 150, 1313, 10.1001/archinte.1990.00390180119022 Vega, 1990, Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations, JAMA, 264, 2759, 10.1001/jama.1990.03450210059033 Grundy, 1988, HMG-CoA reductase inhibitors for treatment of hypercholesterolemia, N Engl J Med, 319, 24, 10.1056/NEJM198807073190105 Ginsberg, 1998, Effects of statins on triglyceride metabolism, Am J Cardiol, 81 A, 32B, 10.1016/S0002-9149(98)00035-6 Vega, 1998, Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men, Am J Cardiol, 81 A, 36B, 10.1016/S0002-9149(98)00036-8 Stein, 1998, Comparison of statins in hypertriglyceridemia, Am J Cardiol, 81 A, 66B, 10.1016/S0002-9149(98)00041-1 Cabezas, 1993, Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion, Metab Clin Exp, 42, 497, 10.1016/0026-0495(93)90109-2 Vega, 1990, Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins, J Intern Med, 227, 81, 10.1111/j.1365-2796.1990.tb00124.x Mitropoulos, 1997, Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids: the Oxford Cholesterol Study Group, Eur Heart J, 18, 235, 10.1093/oxfordjournals.eurheartj.a015225 Contacos, 1993, Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia, Arterioscler Thromb, 13, 1755, 10.1161/01.ATV.13.12.1755 Cheung, 1993, Effects of pravastatin on apolipoprotein-specific, high-density lipoprotein subpopulations and low-density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia, Atherosclerosis, 102, 107, 10.1016/0021-9150(93)90089-D Superko, 1997, Effect of HMG-CoA reductase inhibitor (fluvastatin) on LDL peak particle diameter, Am J Cardiol, 80, 78, 10.1016/S0002-9149(97)00288-9 Franceschini, 1994, Pravastatin effectively lowers LDL cholesterol in familial-combined hyperlipidemia without changing LDL subclass pattern, Arterioscler Thromb, 14, 1569, 10.1161/01.ATV.14.10.1569 Yuan, 1991, Effects of fluvastatin (XU 62–320), an HMG-CoA reductase inhibitor, on the distribution and composition of lowdensity lipoprotein subspecies in humans, Atherosclerosis, 87, 147, 10.1016/0021-9150(91)90017-W Viterbo, 1992, Low-density lipoprotein particle size changes with lovastatin treatment, Clin Res, 40, 219A Zhao, 1991, Effect of simvastatin on the apparent size of LDL particles in patients with type IIB hyperlipoproteinemia, Clin Chim Acta, 203, 109, 10.1016/0009-8981(91)90283-I Gaw, 1993, Effects of Simvastatin on ApoB metabolism and LDL subfraction distribution, Arterioscler Thromb, 13, 170, 10.1161/01.ATV.13.2.170 de Graaf, 1993, The effect of simvastatin treatment on the low-density lipoprotein subfraction profile and composition in familial hypercholesterolaemia, Neth J Med, 43, 254 Rosenson, 1998, Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-1 Trial, Circulation, 98, I Carpentier, 1998, Atorvastatin substantially reduces small dense LDL subpopulation in patients with coronary heart disease, Circulation, 98, I Homma, 1995, Effects of simvastatin on plasma lipoprotein subtractions, cholesterol esterification rate, and cholesterol ester transfer protein in type II hyperlipoproteinemia, Atherosclerosis, 114, 223, 10.1016/0021-9150(94)05487-4 Athyros, 1997, Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia, Am J Cardiol, 80, 608, 10.1016/S0002-9149(97)00430-X Murdock, 1999, Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders, Am Heart J, 138, 151, 10.1016/S0002-8703(99)70261-9 Grundy, 1976, Chylomicron clearance in normal and hyperlipidemic man, Metabolism, 25, 1225, 10.1016/S0026-0495(76)80006-6 Garg, 1990, Nicotinic acid as therapy for dyslipidemia in non-insulindependent diabetes mellitus, JAMA, 264, 723, 10.1001/jama.1990.03450060069031 Grundy, 1981, Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man, J Lipid Res, 22, 24, 10.1016/S0022-2275(20)34737-4 Guyton, 1998, Effect of niacin on atherosclerotic cardiovascular disease, Am J Cardiol, 82, 18U, 10.1016/S0002-9149(98)00767-X 1975, Clofibrate and niacin in coronary heart disease, JAMA, 231, 360, 10.1001/jama.1975.03240160024021 Canner, 1986, Fifteen-year mortality in coronary drug project patients: long-term benefit with niacin, J Am Coll Cardiol, 8, 1245, 10.1016/S0735-1097(86)80293-5 Brown, 1990, Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B, N Engl J Med, 323, 1289, 10.1056/NEJM199011083231901 Morgan, 1996, Treatment effect of niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial, J Cardiovasc Pharmacol, 1, 195, 10.1177/107424849600100302 Guyton, 1998, Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia, Am J Cardiol, 82, 737, 10.1016/S0002-9149(98)00448-2 Morgan, 1998, A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients, Am J Cardiol, 82, 29U, 10.1016/S0002-9149(98)00732-2 Knopp, 1998, Clinical profiles of plain versus sustained-release niacin (Niaspan) and the physiologic rationale for nighttime dosing, Am J Cardiol, 82, 24U, 10.1016/S0002-9149(98)00847-9 Kashyap, 1998, Mechanistic studies of high-density lipoproteins, Am J Cardiol, 82, 42U, 10.1016/S0002-9149(98)00813-3 Vega, 1985, Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease: effects on metabolism of low-density lipoproteins, JAMA, 253, 2398, 10.1001/jama.1985.03350400082026 Superko, 1992, Differential effects of nicotinic acid in subjects with different LDL subclass patterns, Atherosclerosis, 95, 69, 10.1016/0021-9150(92)90177-I Superko, 1994, KOS Investigators. Effect of nicotinic acid on LDL subclass patterns, Circulation, 90, I Superko, 1995, Reduction of small, dense LDL by gemfibrozil in LDL subclass pattern B, Circulation, 92, I Zambon, 1998, Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol, Arterioscler Thromb Vasc Biol, 18, 1723, 10.1161/01.ATV.18.11.1723 Capuzzi, 1998, Advances in dyslipidemia, Am J Cardiol, 82, 850 Egan, 1999, Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) Pilot Study, Am J Cardiol, 83, 569, 10.1016/S0002-9149(98)00915-1 Saku, 1985, Mechanism of action of gemfibrozil on lipoprotein metabolism, J Clin Invest, 75, 1702, 10.1172/JCI111879 Superko, 1997, LDL subclass distribution change in familial combined hyperlipidemia patients following gemfibrozil and niacin treatment, J Am Coll Cardiol, 29, 46A Gaw, 1999, Fibric acid derivatives, 1145 Yuan, 1994, Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy, Atherosclerosis, 110, 1, 10.1016/0021-9150(94)90062-0 Dachet, 1995, Effect of gemfibrozil on the concentration and composition of very-low-density and low-density lipoprotein subfractions in hypertriglyceridemic patients, Atherosclerosis, 113, 1, 10.1016/0021-9150(94)05411-B De Lorgeril, 1999, Lipid-lowering drugs and homocysteine, Lancet, 353, 209, 10.1016/S0140-6736(05)77220-2 East, 1988, Combination drug therapy for familial combined hyperlipidemia, Ann Intern Med, 109, 25, 10.7326/0003-4819-109-1-25 Garg, 1989, Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM, Diabetes, 38, 364, 10.2337/diabetes.38.3.364 Barrett-Connor, 1991, Estrogen and coronary heart disease in women, JAMA, 265, 1861, 10.1001/jama.1991.03460140089033 Guetta, 1996, Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women, Circulation, 93, 1928, 10.1161/01.CIR.93.10.1928 1995, Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial, JAMA, 273, 199, 10.1001/jama.1995.03520270033028 Darling, 1997, Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women, N Engl J Med, 337, 595, 10.1056/NEJM199708283370903 Tikkanen, 1999, Sex hormones, 967 Mosca, 1997, Cardiovascular disease in women, Circulation, 96, 2468, 10.1161/01.CIR.96.7.2468 Hulley, 1998, Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women, JAMA, 280, 605, 10.1001/jama.280.7.605 Lewis, 1998, Effect of pravastatin on cardiovascular events in women after myocardial infarction: the Cholesterol and Recurrent Events (CARE) Trial, J Am Coll Cardiol, 32, 140, 10.1016/S0735-1097(98)00202-2 Walsh, 1999, Lipids: natural history and pharmacologic management, 101 Von Schacky, 1999, The effect of dietary omega-3 fatty acids on coronary atherosclerosis, Ann Intern Med, 130, 554, 10.7326/0003-4819-130-7-199904060-00003 Burr, 1989, Effects of changes in fat, fish and fibre intakes on death and myocardial infarction: Diet and Reinfarction Trial (DART), Lancet, 2, 757, 10.1016/S0140-6736(89)90828-3 Burr, 1994, Diet and reinfarction, Eur Heart J, 15, 1152, 10.1093/oxfordjournals.eurheartj.a060645 Singh, 1997, Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: The Indian experiment of infarct survival-4, Cardiovasc Drug Ther, 11, 485, 10.1023/A:1007757724505 Harris, 1999, Nonpharmacologic treatment of hypertriglyceridemia: focus on fish oils, Clin Cardiol, 22, II-40, 10.1002/clc.4960221408 1999, GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione Trial, Lancet, 354, 447, 10.1016/S0140-6736(99)07072-5 Von Schacky, 1985, Long-term effects of dietary marine omega3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans, J Clin Invest, 76, 1626, 10.1172/JCI112147 Katan, 1995, Fish and heart disease, N Engl J Med, 332, 1024, 10.1056/NEJM199504133321509 Sniderman, 1996, Measurement of apoproteins: time to improve the diagnosis and treatment of the atherogenic dyslipoproteinemias, Clin Chem, 42, 489, 10.1093/clinchem/42.4.489 Rifai, 1992, Measurement of low-density lipoprotein cholesterol in serum: a status report, Clin Chem, 38, 150, 10.1093/clinchem/38.1.150 Kinosian, 1995, Cholesterol and coronary heart disease: predicting risks in men by changes in levels and ratios, J Investig Med, 43, 443 Kinosian, 1994, Cholesterol and coronary heart disease: Predicting risks by levels and ratios, Ann Intern Med, 121, 641, 10.7326/0003-4819-121-9-199411010-00002 Gaziano, 1997, Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction, Circulation, 96, 2520, 10.1161/01.CIR.96.8.2520 Abate, 1993, Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100, Atherosclerosis, 104, 159, 10.1016/0021-9150(93)90187-Y Vega, 1990, Does measurement of apolipoprotein B have a place in cholesterol management?, Arteriosclerosis, 10, 668, 10.1161/01.ATV.10.5.668 Havel, 1995, Management of primary hyperlipidemia, N Engl J Med, 332, 1491, 10.1056/NEJM199506013322207 Garg, 1990, Management of dyslipidemia in NIDDM, Diabetes Care, 13, 153, 10.2337/diacare.13.2.153 Vega, 1990, Does measurement of apolipoprotein B have a place in cholesterol management?, Arteriosclerosis, 10, 668, 10.1161/01.ATV.10.5.668 Sniderman, 1980, Association of coronary atherosclerosis with hyperapobetalipoproteinemia (increased protein but normal cholesterol levels in human plasma low density (B) lipoproteins), 77, 604 Brown, 1990, Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B, N Engl J Med, 323, 1289, 10.1056/NEJM199011083231901 Lamarche, 1995, Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec cardiovascular study), Am J Cardiol, 75, 1189, 10.1016/S0002-9149(99)80760-7 Sniderman, 1997, To (measure apo) B or not to (measure apo) B: a critique of modern medical decision making, Clin Chem, 43, 1310, 10.1093/clinchem/43.8.1310 Ballantyne, 1998, Current thinking in lipid lowering, Am J Med, 104, 33S, 10.1016/S0002-9343(98)00186-7 Mahley, 1984, Plasma lipoproteins: apolipoprotein structure and function, J Lipid Res, 25, 1277, 10.1016/S0022-2275(20)34443-6 Puchois, 1987, Apolipoprotein A-I-containing lipoproteins in coronary artery disease, Atherosclerosis, 68, 35, 10.1016/0021-9150(87)90091-8 Fruchart, 1992, Apolipoprotein A-containing lipoprotein particles: physiologic role, quantification, and clinical significance, Clin Chem, 38, 793, 10.1093/clinchem/38.6.793 Krauss, 1992, Detection and quantitation of LDL subfractions, Curf Opin Lipidol, 3, 377, 10.1097/00041433-199212000-00005 Krauss, 1982, Identification of multiple subclasses of plasma low density lipoproteins in normal humans, J Lipid Res, 23, 97, 10.1016/S0022-2275(20)38178-5 Scheffer, 1997, Measurement of low-density lipoprotein particle size by high-performance gel-filtration chromatography, Clin Chem, 43, 1904, 10.1093/clinchem/43.10.1904 Scheffer, 1998, Measurement of LDL particle size in whole plasma and serum by high performance gel-filtration chromatography using a fluorescent lipid probe, Clin Chem, 44, 2148, 10.1093/clinchem/44.10.2148 Otvos, 1997, Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy, 497 Superko, 1997, The atherogenic lipoprotein profile, Science and Medicine, 4, 36 Superko, 1996, Lipid disorders contributing to coronary heart disease: an update, Curr Prob Cardiol, 21, 733, 10.1016/S0146-2806(96)80005-3 Hodis, 1995, Triglyceride-rich lipoproteins and the progression of coronary artery disease, Curr Opin Lipidol, 6, 209, 10.1097/00041433-199508000-00004 Havel, 1990, Role of triglyceride-rich lipoproteins in progression of atherosclerosis, Circulation, 82, 694, 10.1161/01.CIR.81.2.694 Hamsten, 1996, Triglycerides and coronary heart disease: has epidemiology given us the right answer?, 41 Karpe, 1995, Quantification of postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100, Arterioscler Thromb Vasc Biol, 15, 199, 10.1161/01.ATV.15.2.199 Kugiyama, 1999, Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease, Circulation, 99, 2858, 10.1161/01.CIR.99.22.2858